Australia markets closed

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.72-0.50 (-5.42%)
At close: 4:00PM EDT
9.00 +0.28 (+3.21%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.22
Open9.33
Bid8.45 x 1800
Ask8.74 x 800
Day's range8.66 - 9.33
52-week range6.68 - 53.75
Volume498,798
Avg. volume1,032,864
Market cap1.003B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.18
Earnings date10 Nov 2021 - 15 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est18.00
  • GlobeNewswire

    Immunovant to Participate in Roivant R&D Day 2021

    NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat during Roivant R&D Day 2021 on Tuesday, September 28, 2021 at 4:00 p.m. ET. A live webcast of the event can be accessed at www.tinyurl.com/roivant. A replay of the event will be archived under the β€˜Events’

  • GlobeNewswire

    Immunovant Appoints Renee Barnett as Chief Financial Officer

    Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to hav

  • Zacks

    Immunovant, Inc. (IMVT) Up 9.3% Since Last Earnings Report: Can It Continue?

    Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.